ABSTRACT
Human cases of dengue virus based on the National Dengue Control Plan were compared with the molecular detection of the dengue virus in trapped mosquitoes, verifying the prediction and efficacy potentials of vector control between the two methodologies in a city with three endemic frontiers. Molecular detection of dengue virus in trapped mosquitoes was significantly higher than in human cases (p = 0.0435). Thus, molecular detection could be used as an early indicator to help prevent more human cases of dengue.
Subject(s)
Aedes/virology , Dengue Virus/isolation & purification , Dengue/prevention & control , Animals , Brazil/epidemiology , Dengue/epidemiology , Endemic Diseases , Female , Humans , MaleABSTRACT
RESUMO O objetivo deste estudo foi realizar uma revisão sistemática para avaliar a eficácia e a segurança de terapias livres de interferon para hepatite C em pacientes coinfectados com o Vírus da Imunodeficiência Humana. Ao todo, 10 ensaios clínicos foram incluídos em um total de 1.626 pacientes coinfectados com o Vírus da Hepatite C/Vírus da Imunodeficiência Humana, em sua maioria, portadores do genótipo 1, e tratados principalmente por 12 ou 24 semanas. Os pacientes apresentaram taxas de aproximadamente 91% para desfechos de eficácia, enquanto descontinuações por eventos adversos foram inferiores a 3%. Desta forma, as terapias livres de interferon aparecem como uma boa opção para tratamento da hepatite C crônica no grupo de pacientes coinfectados com o Vírus da Imunodeficiência Humana.
ABSTRACT The aim of this study was to conduct a systematic review to evaluate the efficacy and safety of interferon-free therapies for hepatitis C in patients coinfected with the Human Immunodeficiency Virus. In all, 10 clinical trials were included in a total of 1.626 patients coinfected with Hepatitis C Virus/Human Immunodeficiency Virus, mostly, carriers of genotype 1, and treated mainly for 12 or 24 weeks. Patients presented rates of approximately 91% for efficacy outcomes, while discontinuations due to adverse events were less than 3%. In this way, interferon-free therapies appear as a good option for the treatment of chronic hepatitis C in the group of patients coinfected with Human Immunodeficiency Virus.
